Five-year survival for Ewing sarcoma depends heavily on whether the cancer has spread at diagnosis. For children and adolescents with localized disease, roughly 70 to 85 percent survive at least five years with modern treatment, while those who present with visible metastases face a five-year survival closer to 40 to 50 percent. That gap between localized and metastatic disease is the single most important dividing line in Ewing sarcoma prognosis, but it is far from the only one. Tumor size, where in the body the cancer arises, how well the tumor responds to chemotherapy, the patient’s age, and even specific mutations inside the tumor cells all shift the outlook in ways that a simple stage-based number cannot capture.
Survival Rates for Localized Disease
Most Ewing sarcoma cases are diagnosed in children and teenagers, and the majority of the survival data comes from pediatric oncology trials. A large analysis of pediatric patients in the United States found an overall five-year survival of about 74 percent across all stages combined, with localized cases reaching roughly 85 percent.1PubMed Central. Ewing Sarcoma in the Pediatric Population: Predictors of Survival Within the United States Those numbers reflect modern multi-drug chemotherapy protocols, which pushed survival from single digits in the pre-chemotherapy era to around 70 percent for localized disease over the past few decades.2PubMed Central. Chemotherapy in Ewing’s sarcoma
An important advance that contributed to those numbers is interval-compressed chemotherapy, where treatment cycles are given every two weeks instead of every three. A landmark Children’s Oncology Group trial showed that this intensified schedule improved ten-year event-free survival from about 61 percent to 70 percent and ten-year overall survival from 69 percent to 76 percent for localized Ewing sarcoma.3PubMed Central. Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children’s Oncology Group Study AEWS0031 That schedule is now the standard of care in North America. Importantly, the benefit held even in patients with adverse risk features such as pelvic tumors or large tumor volumes.
Survival Rates for Metastatic Disease
When Ewing sarcoma has already spread at diagnosis, the picture darkens considerably. The same pediatric database that reported 85 percent five-year survival for localized tumors found about 50 percent for those with metastases at presentation.1PubMed Central. Ewing Sarcoma in the Pediatric Population: Predictors of Survival Within the United States A French real-world study of metastatic patients reported a median overall survival of roughly 27 months and a three-year survival of about 40 percent in the broader metastatic cohort; patients who presented with metastases from the outset fared somewhat better, with a median survival closer to 31 months and a three-year survival near 47 percent.4PubMed Central. Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real‐Life National Setting Over a Decade
Not all metastases carry the same weight. Where the cancer spreads matters. Patients whose disease has spread only to the lungs tend to do better than those with bone metastases. One study directly comparing the two patterns found that bone-only metastasis carried roughly double the hazard of cancer-specific death compared with lung-only metastasis.5Journal of Bone Oncology. The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone When both lung and bone metastases are present, outcomes are worse still, with each metastatic site compounding the risk.6PubMed Central. Lung and bone metastases patterns in Ewing sarcoma: Chemotherapy improves overall survival
Tumor Location and Size
Ewing sarcoma can arise in almost any bone or soft tissue, but where it starts has a real effect on survival. Tumors of the pelvis are widely recognized as the worst-prognosis primary site. A population-based study found that the five-year survival for pelvic Ewing sarcoma was about 50 percent, which was significantly lower than for any other site at every measured time point.7PubMed. Ewing sarcoma of the pelvis: Clinical features and overall survival Pelvic tumors tend to be larger at diagnosis, are more likely to have already metastasized, and are harder to remove surgically with clean margins.
Within the pelvis, certain sub-sites carry even higher risk. An analysis of pelvic cases treated with radiation found that tumors in the ischiopubic-acetabulum region had the highest local failure rate, approaching 38 percent, compared with sacral or iliac tumors.8PubMed Central. Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy Treatment decisions in pelvic disease are especially nuanced. Adding radiation after surgery has been shown to roughly halve local recurrence rates in several studies.9PubMed Central. A Systematic Review on the Role of Postoperative Radiotherapy in Pelvic Ewing Sarcoma For tumors in surgically difficult spots like the sacrum, chemotherapy combined with definitive radiation without surgery may be preferable in selected patients.10PubMed Central. Treatment of pelvic Ewing’s sarcoma: Pros and cons of chemotherapy plus definitive radiotherapy versus surgery
Size matters independently of location. A systematic review identified tumor volume of 200 mL or more (or a largest diameter of 8 cm or more) as a consistent adverse prognostic factor.11PubMed. Prognostic factors for survival in Ewing sarcoma: A systematic review One older but influential study put the difference in stark terms: three-year disease-free survival was 78 percent for tumors under 100 mL versus 17 percent for tumors 100 mL or larger, and that gap held regardless of tumor site.12PubMed Central. Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents Pelvic tumors and tumors in the central skeleton do tend to be discovered at larger sizes, which partly explains why axial location and large volume track together as risk factors.
Chemotherapy Response as a Prognostic Marker
One of the most powerful predictors of outcome only becomes clear after treatment has started: how much of the tumor is killed by initial chemotherapy. The standard approach for Ewing sarcoma is several cycles of chemotherapy before surgery, followed by more chemotherapy afterward. When the removed tumor is examined under a microscope, pathologists assess the percentage of cancer cells that were killed.
Research consistently shows that only patients with 100 percent tumor necrosis, meaning no viable cancer cells left in the specimen, should be classified as truly good responders. Those patients have significantly better overall survival, recurrence-free survival, and metastasis-free survival than patients with any residual living tumor.13PubMed. Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcoma An earlier study reinforced the same threshold, finding that the survival advantage held only at 100 percent necrosis, not at 90 percent or 95 percent.14PubMed. Ewing’s sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response
In a single-institution study that broke down outcomes by necrosis grade, patients with complete necrosis had an overall survival of about 93 percent, while those with minimal necrosis had overall survival ranging from 25 to 50 percent depending on the grade.15PubMed. Clinical Outcome of paediatric ewing sarcoma and significance of pathological necrosis for mortality after neoadjuvant chemotherapy This is why the pathology report after surgery is such a critical moment in Ewing sarcoma treatment: it reshapes the expected prognosis and may influence decisions about additional therapy.
PET scans can also offer clues about prognosis. High metabolic activity on a PET scan before treatment, measured by a value called the SUVmax, is associated with worse outcomes. One study found that patients whose initial SUVmax exceeded about 12 had roughly five times the risk of dying compared with those below that threshold.16PubMed Central. 18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone And after treatment, a PET scan that still shows activity is a strong predictor of disease progression.17PubMed. Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET
Age and Survival
Ewing sarcoma is primarily a disease of the young, peaking in the teenage years, but it can occur in adults. Age at diagnosis matters for prognosis, and not in a subtle way. Adults consistently do worse than children and adolescents with the same disease.18PubMed Central. Overall survival comparison between pediatric and adult Ewing sarcoma of bone and adult nomogram construction An older but often-cited series from Memorial Sloan Kettering found that the five-year survival for adults with localized disease was about 49 percent, well below the range reported for children.19PubMed Central. Adults With Ewing’s Sarcoma/Primitive Neuroectodermal Tumor: Adverse Effect of Older Age and Primary Extraosseous Disease on Outcome
A troubling trend has emerged over time. While survival for children and young teenagers has improved dramatically, reaching five-year relative survival of about 70 percent in recent periods, progress for young adults in their twenties and thirties has been much slower. A recent population-based study found that five-year relative survival for the oldest young-adult group stayed flat at roughly 42 percent across the entire study period from 1990 to 2018, even as the youngest patients saw a roughly 20 percentage-point improvement.20PubMed Central. Increasing survival disparity between children, adolescents, and young adults with osteosarcoma or Ewing sarcoma of bone from 1990 to 2024 The reasons are not entirely clear but likely include less access to pediatric cancer centers, lower enrollment in clinical trials, and possible biological differences in adult tumors.
A parallel analysis of adult Ewing sarcoma focusing on those with localized disease did show improvement over time: five-year overall survival rose from about 60 percent in the full cohort to roughly 73 percent among patients treated in a more recent era.21PubMed Central. Adult ewing sarcoma: survival and local control outcomes in 102 patients with localized disease So while adults still lag behind children, the gap may narrow as more adults are treated at specialized centers using the same intensive pediatric protocols.
Molecular Markers That Shift Prognosis
Ewing sarcoma is defined by a characteristic gene fusion, most commonly involving the EWSR1 and FLI1 genes. For years, the specific type of fusion seemed to matter: so-called type 1 fusions were associated with better outcomes. However, modern intensive chemotherapy appears to have erased that difference. A Children’s Oncology Group analysis found that patients with type 1 and non-type 1 fusions now have equivalent five-year event-free survival and overall survival.22PubMed Central. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma
What does still matter at the molecular level are additional mutations beyond the defining fusion. Two genes stand out. Mutations in STAG2, a gene involved in how chromosomes separate during cell division, and TP53, the most commonly mutated tumor suppressor in cancer, both independently worsen the outlook. A recent large molecular characterization study found that STAG2-mutated tumors had a five-year relapse rate of about 53 percent versus 21 percent for tumors without the mutation. In a multivariable analysis adjusting for other risk factors, STAG2 remained the only molecular biomarker that held up as an independent predictor of relapse.23PubMed Central. Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma
When both STAG2 and TP53 are mutated in the same tumor, the prognosis is especially grim. An earlier genomic analysis showed that these two mutations often occur together and define an aggressive subtype requiring alternative treatment strategies.24PubMed Central. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations A Children’s Oncology Group report confirmed this, estimating that five-year event-free survival for double-mutant tumors was only about 25 percent, compared with 50 percent or higher for other groups.25British Journal of Cancer. Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma These markers are not yet used to change treatment routines in standard practice, but they are actively being studied as tools for risk stratification in clinical trials.
Another emerging biomarker is circulating tumor DNA, fragments of tumor genetic material detectable in a blood draw. In localized Ewing sarcoma, patients with detectable ctDNA at diagnosis had a three-year event-free survival of about 49 percent compared with 82 percent for those without detectable ctDNA.26British Journal of Cancer. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma This biomarker remained prognostic even after adjusting for age and pelvic tumor site, and it holds promise as a non-invasive way to monitor disease and guide treatment intensity in the future.
Relapse and What Happens After Recurrence
Even among patients who initially respond well, about 20 to 30 percent of those with localized disease will eventually relapse. When Ewing sarcoma comes back, the outlook depends largely on two things: how long ago the original diagnosis was and whether the initial disease was localized or metastatic.
A Children’s Oncology Group report on first recurrence found that two-year survival after relapse was roughly 49 percent for patients whose cancer was originally localized and about 26 percent for those who were initially metastatic. The timing of the relapse was even more telling. Among patients originally diagnosed with localized disease, those who relapsed more than two years after diagnosis had a two-year post-relapse survival of about 71 percent, compared with just 31 percent for those who relapsed sooner.27Journal of Clinical Oncology. Survival and prognostic factors of patients with Ewing sarcoma at first recurrence following modern era multimodal therapy The same pattern held for initially metastatic patients: late relapse predicted much better survival than early relapse. An independent single-center study confirmed that recurrence more than two years from diagnosis was the only independent predictor of better post-relapse outcome.28PubMed Central. Prognostic factors and outcome of relapsed/progressive pediatric Ewing sarcoma
For relapsed or high-risk patients, high-dose chemotherapy followed by autologous stem cell transplant is sometimes considered. A systematic review suggested that this approach may improve survival compared with conventional chemotherapy alone for relapsed cases, though randomized trial data confirming the benefit is still lacking.29PubMed Central. Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing’s Sarcoma A single-institution study of high-risk patients treated with this approach reported a five-year overall survival of about 55 percent, with patients who achieved a complete response before transplant doing better.30PubMed Central. High-dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma
Racial and Ethnic Disparities
Ewing sarcoma is overwhelmingly more common in white populations, but when it does occur in Black, Hispanic, or Asian patients, outcomes are often worse. A large Surveillance, Epidemiology, and End Results (SEER) database analysis found that Black patients had a five-year overall survival of about 41 percent versus roughly 52 percent for non-Hispanic white patients. After adjusting for age, year of diagnosis, metastatic status, and pelvic tumor site, Black patients still had nearly double the hazard of death, and Hispanic and Asian patients also had elevated risk compared with non-Hispanic whites.31PubMed Central. Ethnic and racial differences in patients with Ewing sarcoma
Part of the disparity appears related to stage at diagnosis: non-Hispanic Black and Hispanic patients are more likely to present with advanced-stage disease. They are also less likely to receive radiation therapy. Despite overall improvements in five-year survival from the mid-50s percent to about 70 percent over recent decades, the gap between racial and ethnic groups has actually widened.32PubMed. Racial and ethnic disparities in treatment and survival of pediatric sarcoma Even when the analysis is restricted to patients without metastases at diagnosis, Hispanic patients in one state-level study still had more than double the hazard of death compared with non-Hispanic white patients.33PubMed Central. Disparities in incidence and survival for patients with Ewing sarcoma in Florida Whether these disparities reflect differences in access to specialized centers, biological variation, delays in diagnosis, or some combination remains an active area of research.
Life After Ewing Sarcoma
For the growing number of long-term survivors, the cancer story does not end with remission. A major study from the Childhood Cancer Survivor Study reported that cumulative mortality among Ewing sarcoma survivors was about 25 percent by 25 years after diagnosis, with a death rate more than 13 times that of the general population. Women were hit harder, with a standardized mortality ratio over 23.34PubMed Central. Long-term Survivors of Childhood Ewing Sarcoma: Report From the Childhood Cancer Survivor Study
Most of the excess late mortality is driven by recurrence of the original disease, but not all of it. The risk of developing a second, different cancer after treatment was about 9 percent by 25 years, and the risk of dying from causes potentially linked to treatment, such as heart disease and lung problems, was roughly nine times higher than in the general population.34PubMed Central. Long-term Survivors of Childhood Ewing Sarcoma: Report From the Childhood Cancer Survivor Study Compared with their siblings, Ewing sarcoma survivors had about six times the risk of a severe or life-threatening chronic health condition. These late effects are consequences of the aggressive multi-agent chemotherapy and radiation that saved their lives, which is why lifelong follow-up with screening for cardiac, pulmonary, and secondary cancer risks is standard for survivors. The challenge going forward is finding ways to cure Ewing sarcoma while reducing the treatment toxicity that creates these long-term burdens.